Voyager Therapeutics (NASDAQ:VYGR) CEO Sells $53,806.63 in Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) CEO Alfred Sandrock sold 14,197 shares of the stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $3.79, for a total transaction of $53,806.63. Following the completion of the sale, the chief executive officer directly owned 484,060 shares of the company’s stock, valued at $1,834,587.40. This represents a 2.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Alfred Sandrock also recently made the following trade(s):

• On Tuesday, February 10th, Alfred Sandrock sold 12,192 shares of Voyager Therapeutics stock. The shares were sold at an average price of $3.78, for a total transaction of $46,085.76.

Voyager Therapeutics Stock Down 3.1%

Shares of Voyager Therapeutics stock opened at $4.10 on Friday. The company has a market capitalization of $227.96 million, a price-to-earnings ratio of -1.90 and a beta of 1.30. The stock’s 50-day simple moving average is $3.86 and its 200-day simple moving average is $4.12. Voyager Therapeutics, Inc. has a 52 week low of $2.64 and a 52 week high of $5.55.

Wall Street Analysts Forecast Growth

VYGR has been the subject of a number of research reports. HC Wainwright dropped their target price on shares of Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, November 12th. Wall Street Zen cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Finally, Wedbush restated an “outperform” rating and set a $8.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, November 11th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $13.75.

Institutional Trading of Voyager Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wexford Capital LP purchased a new position in Voyager Therapeutics during the third quarter worth $42,000. ProShare Advisors LLC bought a new stake in shares of Voyager Therapeutics in the 4th quarter worth about $44,000. CIBC Asset Management Inc bought a new stake in shares of Voyager Therapeutics in the 4th quarter worth about $45,000. Bank of Montreal Can purchased a new position in shares of Voyager Therapeutics during the 2nd quarter worth about $36,000. Finally, Coldstream Capital Management Inc. bought a new position in Voyager Therapeutics during the 3rd quarter valued at about $55,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.